SGCIA
UTHR icon

Smith Graham & Co Investment Advisors’s United Therapeutics UTHR Stock Holding History

Smith Graham & Co Investment Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-18,605
Closed -$2.52M – 137
2017
Q1 		$2.52M Sell
18,605
-7,230
-28% -$1.1M 0.27% 136
2016
Q4 		$3.71M Sell
25,835
-1,850
-7% -$236K 0.4% 115
2016
Q3 		$3.27M Buy
+27,685
New +$3.33M 0.42% 130

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Smith Graham & Co Investment Advisors's UTHR Position: Q2 2017 in Review

Smith Graham & Co Investment Advisors sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 18,605 shares — an estimated $2.52M sold.

Smith Graham & Co Investment Advisors first reported a position in UTHR in Q3 2016 and held it in 3 quarters. The position peaked at $3.71M in Q4 2016. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

  • Smith Graham & Co Investment Advisors reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Smith Graham & Co Investment Advisors sold 18,605 United Therapeutics shares in Q2 2017, an estimated $2.52M.
  • Smith Graham & Co Investment Advisors first reported a position in United Therapeutics in Q3 2016 and held it in 3 quarters.
  • Smith Graham & Co Investment Advisors's United Therapeutics position peaked at $3.71M in Q4 2016.
  • 373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Smith Graham & Co Investment Advisors's 13F filing for Q2 2017, filed 6 Jul 2017.